Chondrex, Inc.

Collagen Antibody-Induced Arthritis in Mice

Collagen Antibody Induced Arthritis (CAIA) Model:

Collagen induced arthritis (CIA) has been used extensively as a mouse model for rheumatoid arthritis (RA). However, this model requires at least 6-8 weeks to complete a typical study (1-12). To reduce this timeline, Chondrex, Inc. has developed a rapid arthritis model using monoclonal antibodies (mAbs) against type II collagen. By injecting the mAbs into mice, arthritis can be induced within a few days. Additional advantages of this CAIA model include 1) inducing arthritis in various mouse strains, not just CIA-susceptible mice. 2) quick screening and evaluation of anti-inflammatory compounds. 3) studying the roles of individual genes and their products in arthritis development using gene knockout and transgenic mice, 4) studying various relevant inflammatory mediators and factors such as bacterial and viral toxins which may be involved in human RA as described (13-17).

CAIA without LPS:

CIA is mediated by autoantibodies to type II collagen and complement, thus arthritis can be induced by administrating polyclonal antibodies (18-19) or a specific combination of monoclonal antibodies (mAb cocktail) to type II collagen (20-21). These autoreactive antibodies recognize particular antigenic determinants (arthritogenic epitopes) located in the CB11 or CB8 fragment of mouse type II collagen (22-23) depending on the MHC type.

Chondrex, Inc.'s mAb cocktail to induce mouse arthritis is a mixture of 5 unique mAbs, A2-10 (IgG2a), F10-21 (IgG2a), D8-6 (IgG2a), D1-2G (IgG2b), and D2-112 (IgG2b) : two mAbs (F10-21 and D8-6) recognize individual epitopes clustered within the 83 amino acid peptide fragment of LyC-2 (291-374) and three mAbs (A2-10, D1-2G, and D2-112) recognize the 167 amino acid peptide fragment of LyC-1 (124-290) of the CB11 fragment (124-402) of mouse type II collagen (13). These epitopes are highly conserved amino acid sequences in many different species including chicken, mouse, rat, bovine, porcine, monkey, and human (20-21).

CAIA with LPS:

Severe and consistent arthritis can be induced in mice by combining a sub-arthritogenic dose of the mAb cocktail and *Escherichia coli* (*E. coli*) - Lipopolysaccharides (LPS) (13). This model was developed based on the hypothesis (24) that bacterial toxin(s), such as LPS, absorbed through the gastrointestinal tract play a synergistic and pathological role with sub-arthritogenic levels of autoantibodies to type II collagen, triggering arthritis. The advantages of this model over the classic CIA model are multifold. First, synchronized arthritis is induced within a few days with nearly 100% incidence. Second, a variety of mouse strains such as CIA-resistant, T-cell deficient, knockout, and transgenic mice can be used (see Table 2).

A typical time course study of the classic CIA model versus the CAIA model is shown in Figure 1. The CAIA model can reduce the timeline of experiments down to a tenth of that of the classic CIA model.



Figure 1 - CAIA vs. classic CIA (a) Triangles: Arthritis developed in 100% of mice within 24-48 hours after LPS injection and reached a maximum score within 5-7 days in mAb-LPS-induced arthritis model. (b) Circles: in the classic CIA model, it took 4 weeks for the onset of arthritis even in CIA highly susceptible strains such as DBA/1J and B10.RIII mice.

Solid markers = severity of arthritis score
Blank markers = incidence of arthritis (%).

© 2017 Chondrex, Inc. All Rights Reserved, CAIA 2.0, Page 1

2607 151st Place NE
Redmond, WA 98052, USA
Phone: (425) 702-6365 or (888) 246-6373
Fax: (425) 882-3094
www.chondrex.com
support@chondrex.com

Animal Care and Diet:

It is imperative to use 7-8 week old mice for the CAIA model. Older mice may demonstrate lower incidence and disease severity. Specific pathogen free (SPF) housing conditions are recommended over conventional housing conditions, as bacterial contamination may reduce the immune response, resulting in attenuated arthritis. Intestinal bacteria flora varies depending on animal vendors and can affect the host immune system's susceptibility to antigens such as LPS. Some mice are highly susceptible to and killed by LPS injections. Chondrex, Inc. recommends testing LPS toxicity in mice prior to running large studies. Diet considerations for mice are not necessary, however, Chondrex, Inc. recommends a high fat diet, Purina Mouse Chow 5015, widely used for mouse inflammation studies (4). Please contact customer support for guidance regarding animals and housing conditions.

Mouse Strains:

Administrating the anti-type II collagen mAb cocktail bypasses the host's need to generate autoantibodies to type II collagen. Thus, arthritis can be induced in mouse strains which lack CIA-susceptible MHC haplotypes (i.e. H-2q and H-2r). All mouse strains with normal inflammatory responses including complement activation should be susceptible to CAIA. Table 1 lists the strains of mice that have been tested to date.

DBA/1 (H-2q) and B10.RIII (H-2r) mice are susceptible to both CIA and CAIA (13).

Balb/c (H-2d) mice, which are resistant to CIA, are highly susceptible to CAIA (13) and are the most commonly used strain (25-27), being readily available.

C.B-17 scid/scid mice are T-cell deficient mice, but can be used for CAIA as T-cells are not required for inflammation in arthritis (17). These mice may even develop more severe arthritis than T-cell normal strains (unpublished data), as T-cells may play a role in down-regulating inflammation during healing as well as in up-regulating inflammatory reactions.

SWR (H-2q) mice have a CIA-susceptible haplotype, but are resistant to CIA and CAIA due to a C5 deficiency (12). Other C5 deficient mouse strains, B10.D2/oSn (19) and NOD/LtSz scid/scid (27), are also apparently resistant to CAIA.

Nude mice are resistant to CAIA (28) for unknown reasons despite nude rats being highly susceptible to antibody-induced arthritis (29). Nude mice may lack select pro-inflammatory cytokine expression.

Table 1 - Mouse strains commonly used for CIA and CAIA

Mouse Strain	H-2 Type	CIA Susceptibility	Reference	CAIA Susceptibility	Reference	Note
DBA/1	q	High	2, 4, 5	High	13, 20	INFg high
B10.Q	q	High	5	(High)		
B10.G	q	High	5	(High)		
NFR/N	q	High	38	(High)		
SWR	q	Resistant	12	Resistant		C5 deficient
B10.RIII	r	High	5	High	13	Low response: chick and human type II
B10	b	Low	9	(High)		* Need alternative immunization
C57BL/6	b	Low	9	Moderate - High	8, 17, 30	LPS low responder * Need alternative immunization
C57BL/6 beige	b	Resistant	19	Resistant		PMN mutation
C57BL/6 x 129/Sv	b	Low	9	Moderate - High	30, 31	* Need alternative immunization
129/Sv	b	Resistant	9	High	27	
B10.D2/nSn	d	Resistant	19	High	19	
B10.D2/oSn	d	Resistant	19	Resistant	19	C5 deficient
Balb/c	d	Resistant		High	13	
Balb/c nu/nu	d	Resistant		Resistant	28	B & T cell deficient
C3H/He	k	Low	39	(Low)		
B10.S	s	Resistant	5			
SJL/1	s	Moderate	2	(High)		
C.B-17 scid/scid		Resistant		High	17	B & T cell deficient

Parentheses - assumed, but not yet tested
* - Develops arthritis by alternative immunization with Complete Freund's Adjuvant containing *M. tuberculosis*

C57BL/6 mice are most commonly used as parent mice for gene knockout and transgenic mice. Although wild type C57BL/6 mice are apparently low responders to LPS, these mice also develop severe arthritis in CAIA with LPS. However, a higher dose of the mAb cocktail is required such as 5 mg/mouse instead of 1.5 mg/mouse (21, 30).

C57BL/6-backcrossed to 129/Sv mice are commonly used for creating gene knockout mice. Some of these backcrossed mice respond to LPS, thus severe arthritis can be induced with an ordinary 1.5 mg/mouse dose (30-31).

The following gene knockout mice have been used to study the role of genes in CAIA model (29-39).

1) NOS2 knockout mice (30)
2) Osteopontin knockout mice (31)
3) COX-1 and COX-2 knockout mice (32)
4) MMP-2 (gelatinase A) and MMP-3 (gelatinase B) knockout mice (33)
5) $P2X_7$ receptor knockout mice (34)
6) c-Jun N-Terminal Kinase knockout mice (35)
7) Prostaglandin E2 receptor knockout mice (36)
8) CD69 null mice (37)

© 2017 Chondrex, Inc. All Rights Reserved, CAIA 2.0, Page 2

2607 151st Place NE
Redmond, WA 98052, USA
Phone: (425) 702-6365 or (888) 246-6373
Fax: (425) 882-3094
www.chondrex.com
support@chondrex.com

Dose of mAb Cocktail and Administration Route:

Chondrex, Inc. recommends administering the mAb cocktail intravenously (i.e. tail vein). Intraperitoneal (IP) injection can also be used in CAIA high responder strains, however, the severity of arthritis tends to be lower and the period of active inflammatory arthritis shorter. Each investigator must determine the best method for his or her own experimental purpose.

Catalog Number	Amount
53100	100 mg
53040	40 mg
53010	10 mg

a) Induction of CAIA without LPS:

To induce arthritis in CAIA high responder strains (DBA/1 and Balb/c) with the mAb cocktail alone, 6-10 mg of mAb will be required per mouse, depending on mouse age and body weight. For example, inject 5 mg/mouse of mAb on day 0 and then inject an additional 5 mg/mouse on day 1. Arthritis should develop 24-48 hours after the second injection. Again, each investigator must optimize the conditions for inducing arthritis based on his or her experimental needs.

b) Induction of CAIA with LPS:

Bacterial toxins such as LPS (B-cell mitogen), Staphylococcal enterotoxin B (T-cell mitogen), and Mycoplasma arthritidis mitogen (T-cell mitogen) act synergistically with antibodies to type II collagen in arthritis development. Thus, the mAb dose required for inducing arthritis can be reduced in the presence of these toxins. For example, injecting 1.5 mg/mouse of the mAb cocktail on day 0 followed by an LPS injection (25-50 µg) on day 3 can induce arthritis in nearly 100% of CAIA high responding mice, such as Balb/c, DBA/1, B10.RIII, and C.B-17 scid/ scid mice. Inject 5 mg/mouse for CAIA low responding C57BL/6 mice. Arthritis progresses rapidly, and acute inflammation peaks on day 7-10 and persists for 2 weeks. Arthritis can be further exacerbated by an additional LPS injection (25-50 µg) on day 10 or 14. The resulting joint destruction is permanent and can lead to ankylosis even though active inflammation declines after 3 weeks. Table 3 references compounds which have successfully blocked inflammation in the CAIA model.

Evaluating Arthritis:

Disease can be assessed by qualitative clinical score or by determining paw thickness using a Mitutoyo loop handle dial thickness gauge with a round disc. Unlike rat paw volume, mouse paw volume cannot be determined with a plethysmograph because the mouse paw is too small. Chondrex, Inc. provides a scoring system (Table 2) and a supplemental flyer (visit www.chondrex.com).

Table 2 - Qualitative scoring system to assess severity of paw inflammation

Score	Condition
0	Normal
1	Mild, but definite redness and swelling of the ankle or wrist, or apparent redness and swelling limimted to individual digits, regardless of the number of affected digits
2	Moderate redness and swelling of ankle or wrist
3	Severe redness and swelling of the entire paw including digits
4	Maximally inflamed limb involving multiple joints

Table 3 - Compounds that have successfully blocked inflammation in the mAb-induced arthritis model.

Compound	Class	Reference
Oncostatin M	Cytokine	25
Anti-Integrins α1β1, 2β1	Adhesion Molecule	26
Chemically Modified Tetracycline (CollaGenex)	Matrix Inhibitor Metalloproteinase	27 (ACR Abstract)
Anti-CD44 (IM7 Clone)	Adhesion Molecule	Unpublished Data
Dexamethasone (0.15 –0.5 mg/kg)	Glucocorticoid	Unpublished Data
Anti-IL-1β Antibody	Cytokine	17
Anti-TNF-α Antibody	Cytokine	17
Anti-MIP-1α Antibody	Cytokine	17
TACE Inhibitor	TNF Converting Enzyme Inhibitor	37
Methotrexate (0.25 mg/kg, single IM injection) - Effective in p53 knockout mice - Not effective in Balb/c mice	Anti-proliferation Communication	Unpublished Data

© 2017 Chondrex, Inc. All Rights Reserved, CAIA 2.0, Page 3

2607 151st Place NE
Redmond, WA 98052, USA
Phone: (425) 702-6365 or (888) 246-6373
Fax: (425) 882-3094
www.chondrex.com
support@chondrex.com

References :

1. DE Trentham, AS Townes, AH Kang. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 146:857-68, 1977.

2. JS Courtenay, MJ Dallman, AD Dayan, A Martin, B Mosedale. Immunization against heterologous type II collagen induces arthritis in mice. Nature 283: 666-668, 1980.

3. ES Cathcart, KC Hayes, WA Gonnerman, AA Lazzari, C Franzblau. Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen. Lab Invest 54:26-31, 1986.

4. PH Wooley. Collagen-induced arthritis in the mouse. Methods Enzymol 162:361-373, 1988.

5. PH Wooley, *et al.* Type II collagen-induced arthritis in mice. IV. Variations in immunogenetic regulation provide evidence for multiple arthritogenic epitopes on the collagen molecule. J Immunol 135:2443-2451, 1985.

6. R Holmdahl, L Jansson, E Larsson, K Rubin, L Klareskog. Homologous type II collagen induces chronic and progressive arthritis in mice. Arthritis Rheum 29:106, 1986.

7. RA Ortmann and EM Shevach. Susceptibility to collagen-induced arthritis: cytokine-mediated regulation. Clin Immunol 98:109-118, 2001.

8. WC Watson, AS Townes. Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatability complex (MHC) and non-MHC loci. J Exp Med 162:1878-1891, 1985.

9. IK Campbell, JA Hamilton, IP Wicks. Collagen-induced arthritis in C57BL/6 (H-2^b) mice: new insights into an important disease model of rheumatoid arthritis. Eur J Immunol 30:1568-1575, 2000.

10. E Michaelsson, *et al.* T cell recognition of carbohydrates on type II collagen. J Exp Med 180:745-749, 1994.

11. M Anderson, R Holmdahl. Analysis of type II collagen reactive T cells in the mouse. I. Different regulation of autoreactive vs. non-autoreactive anti-type II collagen T cells in the DBA/1 mouse. Eur J Immunol 20:1061-1066, 1990.

12. R Reife, N Loutis, W Watson, K Hasty, J Stuart. SWR mice are resistant to collagen-induced arthritis but produce potentially arthritogenic antibodies. Arthritis Rheum 34:776-781, 1991.

13. K Terato, *et al.* Collagen-induced arthritis in mice: synergistic effect of E.coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity 22:137-147, 1995.

14. S Yoshino, E Sasatomi, Y Mori. Oral administration of lipopolysaccharide exacerbates collagen-induced arthritis in mice. J Immunol 163:3417-3422, 2000.

15. BC Cole, MM. Griffiths. Triggering and exacerbation of autoimmune arthritis by the Mycoplasma Arthritidid superantigen MAM. Arthritis Rheum 36: 994-1002, 1993.

16. Y Takaoka, H Nagai, M Tanahashi, K Kawada. Cyclosporin A and FK-506 inhibit development of superantigen-potentiated collagen-induced arthritis. Gen Pharmcol 30:777-782, 1998.

17. T Kagari, H Doi and T Shimozato. The importance of IL-1β and TNF-α, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol 169:1459-1466, 2002.

18. JM Stuart, MA Cremer, AS Townes, AH Kang. Type II collagen-induced arthritis in rats: passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med 155:1-16, 1982.

19. WC Watson, PS Brown, JA Pitcock, AS Townes. Passive transfer studies with type II collagen antibody in B10.D2/old and new line and C57BL/6 normal and beige (Chediak-Higashi) strains: evidence of important roles for C5 and multiple inflammatory cell types in the development of erosive arthritis. Arthritis Rheum 30:460-5, 1987.

© 2017 Chondrex, Inc. All Rights Reserved, CAIA 2.0, Page 4

2607 151st Place NE
Redmond, WA 98052, USA

Phone: (425) 702-6365 or (888) 246-6373
Fax: (425) 882-3094

www.chondrex.com
support@chondrex.com

20. K Terato, *et al.* Induction of arthritis with monoclonal antibodies to collagen. J Immunol 148:2103-2108, 1992.

21. Hutamekalin, P., Saito, T., Yamaki, K, *et al.* Collagen antibody-induced arthritis in mice: Development of a new arthritogenic 5-clone cocktail of monoclonal anti-type II collagen antibodies. Journal of Immunological Methods, 343(1), 49-55, 2009

22. K Terato, *et al.* Collagen-induced arthritis in mice. Localization of an arthritogenic determinant to a fragment of the type II collagen molecule. J Exp Med 162:637-646, 1985.

23. LK Myers, H Miyahara, K Terato, JM Seyer, AH Kang. Collagen-induced arthritis in B10.RIII mice (H-2^r): identification of an arthritogenic T cell determinant. Immunol 84:509-513, 1995.

24. K Terato, *et al.* Induction of chronic autoimmune arthritis in DBA/1 mice by oral administration of type II collagen and Escherichia Coli Lipopolysaccharide. British J Rheum 35:828-838, 1996.

25. P Wallace, *et al.* Regulation of inflammatory responses by Oncostatin M. J Immunol 162:5547-5555, 1999.

26. A de Fougerolles, *et al.* Regulation of inflammation by collagen-binding integrins α1β1 and α2β1 in models of hypersensitivity and arthritis. J Clin Invest. 105:721-729, 2000.

27. FS Larox, *et al.* A novel model of polyarthritis induced in mice using monoclonal antibodies to type II collagen. Characterization and effects of chemically modified tetracycline. Arthritis Rheum 42:s121 (supplement).

28. Y Tsuchiya, M Maeda, K Hanada, *et al.* Mouse arthritis model induced by anti-type II collagen monoclonal antibody cocktail: Difference in distribution of diseased joints by strain and immunodeficient status. Proc Japanese Society Animal Models for Human Diseases.19:14-22, 2003.

29. K Takagishi, *et al.* Serum transfer of collagen arthritis in congenitally athymic nude rats. J Immunol 134:3864-3867, 1985.

30. H Kato, *et al.* Effect of NOS2 gene deficiency on the development of autoantibody mediated arthritis and subsequent articular cartilage degeneration. J Rheumatology 30:247-255, 2003.

31. K Yumoto, *et al.* Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. PNAS 99: 4556-45561, 2002.

32. LK Myers, *et al.* The genetic ablation of cyclooxigenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum 43:2687-2693, 2000.

33. T Itoh, *et al.* The role of matrix metalloproteinase-2 and metalloproteinase-9 in antibody-induced arthritis. J Immunol 169:2643-2647, 2002.

34. JM Labasi, *et al.* Absence of the $P2X_7$ receptor alters leukocyte function and attenuates an inflammatory response. J Immunol 168:6436-6445, 2002.

35. Z Han, *et al.* Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 818-823, 2002.

36. JM McCoy, *et al.* The role of prostaglandin E2 receptor in the pathogenesis of rheumatoid arthritis. J Clin Invest 110:651-658, 2002.

37. RC Newton, *et al.* Biology of TACE inhibitor. Ann Rheum Dis 60:iii25-iii32, 2001.

38. R Holmdahl, L Jannson, M Anderson, *et al.* Immunogenetics of type II collagen autoimmunity and susceptibility to collagen arthritis. Immunology 65:305-10, 1988.

39. S Thornton, G Boivin, KN Kim, *et al.* Heterogeneous effect of IL-2 on collagen-induced arthritis. J Immunol 165:1557-1563, 2000.

© 2017 Chondrex, Inc. All Rights Reserved, CAIA 2.0, Page 5

2607 151st Place NE
Redmond, WA 98052, USA

Phone: (425) 702-6365 or (888) 246-6373
Fax: (425) 882-3094

www.chondrex.com
support@chondrex.com